Treatment of luteal phase defects in assisted reproduction
- PMID: 23621507
- DOI: 10.2174/1389450111314080002
Treatment of luteal phase defects in assisted reproduction
Abstract
Abnormal luteal function is a common issue in assisted reproduction techniques associated with ovarian stimulation probably due to low levels of LH in the middle and in the late luteal phase. This defect seems to be associated with supraphysiological steroid levels at the end of follicular phase. The luteal phase insufficiency has not got a diagnostic test which has proven reliable in a clinical setting. Luteal phase after ovarian stimulation becomes shorter and insufficient, resulting in lower pregnancy rates. Luteal phase support with progesterone or hCG improves pregnancy outcomes and no differences are found among different routes of administration. However, hCG increases the risk of ovarian hyperstimulation syndrome. In relation to the length of luteal support, the day of starting it remains controversial and it does not seem necessary to continue once a pregnancy has been established. After GnRHa triggering ovulation, intensive luteal support or hCG bolus can overcome the defect in luteal phase, but more studies are needed to show the LH utility as support.
Similar articles
-
Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.Eur J Obstet Gynecol Reprod Biol. 2006 May 1;126(1):87-92. doi: 10.1016/j.ejogrb.2005.11.013. Epub 2005 Dec 22. Eur J Obstet Gynecol Reprod Biol. 2006. PMID: 16377065 Clinical Trial.
-
Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.Hum Reprod. 2015 Oct;30(10):2387-95. doi: 10.1093/humrep/dev184. Epub 2015 Jul 23. Hum Reprod. 2015. PMID: 26209535 Clinical Trial.
-
Hormonal profile in early luteal phase after triggering ovulation with gonadotropin-releasing hormone agonist in high-responder patients.Front Endocrinol (Lausanne). 2022 Aug 15;13:834627. doi: 10.3389/fendo.2022.834627. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36046787 Free PMC article.
-
GnRHa to trigger final oocyte maturation: a time to reconsider.Hum Reprod. 2009 Oct;24(10):2389-94. doi: 10.1093/humrep/dep246. Epub 2009 Jul 16. Hum Reprod. 2009. PMID: 19608565 Review.
-
The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives.Reprod Biomed Online. 2012 Feb;24(2):134-41. doi: 10.1016/j.rbmo.2011.11.001. Epub 2011 Nov 9. Reprod Biomed Online. 2012. PMID: 22197130 Review.
Cited by
-
The relationship between estradiol-progesterone alterations after ovulation trigger and treatment success in intrauterine insemination cycles.Turk J Obstet Gynecol. 2016 Jun;13(2):56-61. doi: 10.4274/tjod.45656. Epub 2016 Jun 15. Turk J Obstet Gynecol. 2016. PMID: 28913092 Free PMC article.
-
Addition of gonadotropin releasing hormone agonist for luteal phase support in in-vitro fertilization: an analysis of 2739 cycles.J Turk Ger Gynecol Assoc. 2015 Jun 1;16(2):96-101. doi: 10.5152/jtgga.2015.15007. eCollection 2015. J Turk Ger Gynecol Assoc. 2015. PMID: 26097392 Free PMC article.
-
Estrogen supplementation to progesterone as luteal phase support in patients undergoing in vitro fertilization: systematic review and meta-analysis.Medicine (Baltimore). 2015 Feb;94(8):e459. doi: 10.1097/MD.0000000000000459. Medicine (Baltimore). 2015. PMID: 25715250 Free PMC article.
-
Luteal phase support for assisted reproduction cycles.Cochrane Database Syst Rev. 2015 Jul 7;2015(7):CD009154. doi: 10.1002/14651858.CD009154.pub3. Cochrane Database Syst Rev. 2015. PMID: 26148507 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical